Search results for "myopia"

showing 10 items of 165 documents

Corneal Biomechanics, Retinal Nerve Fiber Layer, and Optic Disc in Children

2014

Purpose. To evaluate the possible associations between corneal biomechanical parameters, optic disc morphology, and retinal nerve fiber layer (RNFL) thickness in healthy white Spanish children. Methods. This cross-sectional study included 100 myopic children and 99 emmetropic children as a control group, ranging in age from 6 to 17 years. The Ocular Response Analyzer was used to measure corneal hysteresis (CH) and corneal resistance factor. The optic disc morphology and RNFL thickness were assessed using posterior segment optical coherence tomography (Cirrus HD-OCT). The axial length was measured using an IOLMaster, whereas the central corneal thickness was measured by anterior segment opti…

MaleRetinal Ganglion Cellsmedicine.medical_specialtyAdolescentgenetic structuresOptic DiskNerve fiber layerEmmetropiaWhite PeopleCorneaCorneal biomechanicsNerve FibersCorneaOphthalmologyMyopiaMedicineHumansChildDioptreÓpticabusiness.industryAnatomyHealthy Volunteerseye diseasesScleraBiomechanical PhenomenaPosterior segment of eyeballOphthalmologyAxial Length EyeOptic disc parametersmedicine.anatomical_structureCross-Sectional StudiesSpainOptic nerveFemalesense organsbusinessTomography Optical CoherenceOptometryOptic disc
researchProduct

Heavy versus standard silicone oil in the management of retinal detachment with macular hole in myopic eyes

2011

PURPOSE: The purpose of this study was to compare pars plana vitrectomy (PPV) with 1000 cSt silicone oil endotamponade and PPV with densiron endotamponade for retinal detachment with macular hole and posterior staphyloma in highly myopic eyes. PATIENTS AND METHODS: In a prospective study, 30 eyes of 30 patients were randomly assigned to PPV and densiron (n = 15) or PPV with silicone oil (n = 15). All eyes had laser photocoagulation of the macular hole rim after PPV. Silicone oil or densiron was removed 12 weeks after surgery. Patients were followed-up for 6 months after oil removal. RESULTS: In the densiron group, the retinal reattachment rate was 100% with densiron in situ and 87% after it…

MaleTime FactorsVisual acuityIntraoperative Complicationgenetic structuresmedicine.medical_treatmentVisual AcuityRetinal perforationVitrectomyPostoperative ComplicationsVitrectomySilicone OilsProspective StudiesEndotamponadeIntraoperative ComplicationsMacular holeLaser Coagulationhigh myopic eyeRetinal detachmentGeneral MedicineMiddle AgedTreatment Outcomemedicine.anatomical_structureMyopia Degenerativemacular hole retinal detachmentDrainageFemalemedicine.symptomLaser coagulationDilatation PathologicHumanAdultPars planamedicine.medical_specialtyTime Factorsilicone oilOphthalmologymedicineHumansAgeddensironbusiness.industryRetinal DetachmentRetinal Perforationsmedicine.diseaseeye diseasesProspective StudieOphthalmologyRetinal PerforationPostoperative Complicationsense organsbusiness
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Refractive lens exchange with a multifocal diffractive aspheric intraocular lens

2012

PURPOSE: To evaluate the safety, efficacy and predictability after refractive lens exchange with multifocal diffractive aspheric intraocular lens implantation. METHODS: Sixty eyes of 30 patients underwent bilateral implantation with AcrySof® ReSTOR® SN6AD3 intraocular lens with +4.00 D near addition. Patients were divided into myopic and hyperopic groups. Monocular best corrected visual acuity at distance and near and monocular uncorrected visual acuity at distance and near were measured before and 6 months postoperatively. RESULTS: After surgery, uncorrected visual acuity was 0.08 ± 0.15 and 0.11 ± 0.14 logMAR for the myopic and hyperopic groups, respectively (50% and 46.67% of patients ha…

MaleVisual acuitygenetic structuresDesenho de prótesesmedicine.medical_treatmentVisual AcuityEmmetropiaIntraocular lensProsthesis designMyopia/surgerylaw.inventionNear visionLens Implantation Intraocularlcsh:OphthalmologylawTonometry ocularMyopiaProspective StudiesLenses IntraocularLens crystalline/surgeryAcuidade visualGeneral MedicineMiddle AgedLens (optics)HyperopiaTreatment OutcomeFemalemedicine.symptomLens crystallinemedicine.medical_specialtyVisual acuityMiopiaRefractive lens exchangeProsthesis DesignStatistics NonparametricOphthalmologyLens CrystallinemedicineHumansHyperopia/physiopathologyHipermetropiaCristalinoAgedPhacoemulsificationbusiness.industryReproducibility of ResultsPhacoemulsificationPresbyopiamedicine.diseaseeye diseasesOphthalmologyLens implantation intraocularlcsh:RE1-994OptometryImplantação de lentes intraocularessense organsbusinessArquivos Brasileiros de Oftalmologia
researchProduct

Bilateral implantation of the Acri.LISA bifocal intraocular lens in myopic eyes.

2009

Purpose To asses visual quality after bilateral implantation of the Acri.LISA 366D intraocular lens (IOL) (Carl Zeiss Meditec) in patients with high and low–moderate myopia. Methods A total of 304 eyes of 152 patients had bilateral implantation of the Acri.LISA 366D IOL. The patients were divided into 2 groups: low–moderate myopia (IOL power from 15 to 20.5 D) and high myopia (IOL power from 0 to 14.5 D). Monocular and binocular best-corrected distance visual acuity (BCVA) and best distance-corrected near visual acuity (BCNVA), binocular best distance-corrected intermediate visual acuity (BCIVA), and distance contrast sensitivity (OS) under photopic (85 cd/m2) and mesopic (5 cd/m2) conditio…

MaleVisual acuitygenetic structuresMesopic visionmedicine.medical_treatmentVisual AcuityIntraocular lensExtractionFunctional LateralityTratamiento médico0302 clinical medicineLens Implantation IntraocularMyopiaContrast (vision)MedicineRetinal-Detachmentmedia_commonVistaLenses IntraocularVision BinocularDistanceHigh myopiaRetinal detachmentGeneral MedicineMiddle AgedQualityTreatment OutcomeOftalmologíaFemalemedicine.symptomPhotopic visionRiskmedia_common.quotation_subjectProsthesis DesignContrast Sensitivity03 medical and health sciencesHumansMonocularPhacoemulsificationbusiness.industryMultifocal Iolmedicine.diseaseeye diseasesVisual PerformanceOphthalmology030221 ophthalmology & optometryOptometrysense organsbusiness030217 neurology & neurosurgeryEuropean journal of ophthalmology
researchProduct

Contrast sensitivity after refractive lens exchange with a multifocal diffractive aspheric intraocular lens

2013

Purpose: To evaluate distance and near contrast sensitivity (CS) under photopic and mesopic conditions before and after refractive lens exchange (RLE) and implantation of the aspheric AcrySof ReSTOR (SN6AD3 model) intraocular lens (IOL) Methods: Sixty eyes of 30 consecutive patients after RLE underwent bilateral implantation with the aspheric AcrySof ReSTOR IOL. The patients sample was divided into myopic [n=15, mean spherical equivalent (SE) -6.87± 2.03 diopters (D)] and hyperopic (n=15, mean SE +4.52±1.14 D) groups. Monocular uncorrected visual acuity at distance and near (UCVA and UCNVA, respectively) and monocular best corrected visual acuity at distance and near (BCVA and BCNVA, respec…

Malegenetic structuresMesopic visionmedicine.medical_treatmentVisual AcuityIntraocular lensMyopia/surgerylaw.inventionLens Implantation Intraocularlcsh:OphthalmologylawMyopiaContrast (vision)Prospective StudiesDioptreMathematicsmedia_commonLenses Intraoculareducation.field_of_studyGeneral MedicineMiddle AgedFacoemulsificaciónLens (optics)HiperopiaHyperopiaFemalePhotopic visionmedicine.medical_specialtyMiopíaVisual acuitymedia_common.quotation_subjectPopulationCataract ExtractionContrast SensitivityVision MonocularOphthalmologyImplantación de lentes intraocularesmedicineHumansHyperopia/physiopathologyAgudeza visualeducationCristalinoAgedMonocularPhacoemulsificationDistance PerceptionLens cristalline/surgeryeye diseasesOphthalmologyLens implantation intraocularlcsh:RE1-994Optometrysense organs
researchProduct

Anisometropia of spherical equivalent and astigmatism among myopes: a 23-year follow-up study of prevalence and changes from childhood to adulthood.

2017

Purpose To study anisometropia of spherical equivalent and astigmatism from the onset of myopia at school age to adulthood. Methods A total of 240 myopic schoolchildren (mean age 10.9 years), with no previous spectacles, were recruited during 1983–1984 to a randomized 3-year clinical trial of bifocal treatment of myopia. Examinations with subjective cyclopedic refraction were repeated 3 years later (follow-up 1) for 238 subjects and thereafter at the mean ages of 23.2 (follow-up 2) and 33.9 years (follow-up 3) for 178 and 134 subjects. After exclusions, the 102 subjects who attended all three follow-ups were included in the analyses. Corneal refractive power and astigmatism and anterior cha…

Malegenetic structuresemmetropizationtaittovirheetSpherical equivalentAnisometropiaCornea0302 clinical medicineCornearefractive errorsMyopiaPrevalenceMedicineChildFinlandSchool age childFollow up studiesGeneral MedicineAxial lengthta3142follow-up studyAxial Length Eyemedicine.anatomical_structureEyeglassesDisease ProgressionFemaleseurantatutkimusanisoastigmatismAdultmedicine.medical_specialtyAdolescentlikinäköisyysaxial lengthAstigmatismRefraction Ocular03 medical and health sciencesYoung AdultOphthalmologyHumansAnisometropiabusiness.industryAstigmatismCorneal Topographymedicine.diseaseeye diseasesta3125Ophthalmology030221 ophthalmology & optometrybusinessCorneal astigmatism030217 neurology & neurosurgeryFollow-Up StudiesForecastingActa ophthalmologica
researchProduct

Refractive lens exchange with Acri.LISA bifocal intraocular lens implantation.

2011

PURPOSE To assess efficacy, safety, and predictability after refractive lens exchange (RLE) in patients who had bilateral implantation of an Acri.LISA 366D diffractive bifocal intraocular lens (IOL). METHODS Sixty-six eyes of 33 consecutive patients were examined after RLE who had bilateral implantation of an Acri.LISA bifocal 366D IOL. Eyes were divided into myopic and hyperopic groups. Monocular uncorrected distance visual acuity, best-corrected distance visual acuity (BCVA), uncorrected distance near visual acuity, and best distance-corrected near visual acuity (BCNVA) were recorded preoperatively and 6 months after surgery. RESULTS Efficacy indexes were 0.73 for myopic and 0.85 for hype…

Malemedicine.medical_specialtyDistance visual acuityVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityIntraocular lensRefractive lens exchangeNear visual acuityFunctional Laterality03 medical and health sciences0302 clinical medicineLens Implantation IntraocularOphthalmologymedicineMyopiaHumansIn patientLenses IntraocularPhacoemulsificationbusiness.industryGeneral MedicinePhacoemulsificationPresbyopiaPresbyopiaMiddle Agedmedicine.diseaseeye diseasesOphthalmologyHyperopiaTreatment Outcome030221 ophthalmology & optometryFemalesense organsmedicine.symptombusiness030217 neurology & neurosurgeryEuropean journal of ophthalmology
researchProduct